Effect Of Preoperative Chemotherapy On Short-Term Outcome After Pancreatic Resection

PREOPERATIVE CHEMOTHERAPY DOES NOT ADVERSELY AFFECT SHORT-TERM OUTCOME AFTER PANCREATIC RESECTION.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01278368

Enrollment

150

Registered

2011-01-17

Start date

2003-01-31

Completion date

2011-12-31

Last updated

2012-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Pancreatic Adenocarcinoma

Keywords

pancreatic cancer, neoadjuvant chemotherapy

Brief summary

No comparative trial investigating the effect of preoperative chemotherapy for locally advanced pancreatic cancer on short-term postoperative outcome has been published so far. The aim of the present study is to assess the potential impact of preoperative chemotherapy on short-term postoperative outcome after pancreatic resection in a case-matched series of cancer patients.

Detailed description

Between 2003 and 2011, patients with locally advanced (stage III) pancreatic cancer who were treated with preoperative chemotherapy (PCHT) underwent surgical resection. Each patient was matched with the closest two patients with pancreatic cancer ( control group ) selected from our prospective electronic database who met the following match criteria: age (+/- 3 years), gender, ASA score, type of resection, pancreatic duct diameter (+/- 1 mm), and tumour size (+/- 5 mm).

Interventions

PROCEDUREPancreatic resection after preoperative chemotherapy

Pancreatic resection after preoperative chemotherapy

PROCEDUREPancreatic resection

Pancreatic resection

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of pancreatic cancer * Preoperative chemotherapy * Pancreatic resection

Exclusion criteria

* Metastatic disease * ASA score 4

Design outcomes

Primary

Measure	Time frame
Postoperative morbidity rate	Postoperative. From 0 to 30 days after discharge

Secondary

Measure	Time frame
Postoperative mortality	Postoperative. From 0 to 30 days after discharge
Length of hospital stay (LOS)	Postoperative. From 0 to 30 days after discharge

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026